Biogen Idec Inc $329.99

up +2.41


18/9/2014 04:00 PM  |  NASDAQ : BIIB  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BIIB Trend Analysis - it has outperformed the S&P 500 by 19%

Partner Headlines

  1. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga
  2. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD
  3. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD
  4. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts
  5. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  6. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD
  7. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech Joneses

    Benzinga
  8. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, ...

    Benzinga
  9. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA ...

    Benzinga
  10. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD
  11. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD
  12. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts
  13. Allianz's Analyst Likes Biogen, Celgene & Gilead

    Benzinga
  14. Indexes Trim Losses But Remain Lower At Midday

    IBD
  15. Biogen: Moving From Collaboration To Innovation

    IBD
  16. Economic Data Fuel Another All-Time High For S&P 500

    IBD
  17. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  18. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD
  19. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD
  20. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD
  21. Biogen's buy rating reaffirmed

    IBD
  22. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval

    Benzinga
  23. Perrigo Regains Some Lost Ground On Fiscal Q4 Beat

    IBD
  24. Perrigo Q4 Beats Estimates, But Guidance Misses

    IBD
  25. Tech, Health Care Lead Q2 Earnings Beats

    IBD
  26. #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq

    Benzinga
  27. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  28. Why Investors Should Closely Watch Celgene

    Benzinga
  29. Biotech Gets A Lift On Popular Drug, Strong Pipeline

    IBD
  30. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus
  31. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus
  32. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD
  33. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  34. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  35. Biogen, Gilead Profits Soar

    IBD
  36. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  37. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD
  38. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  39. Vertex Is Poised For An Earnings Breakout

    Benzinga
  40. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout ...

    Benzinga
  41. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD
  42. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  43. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  44. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  45. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD
  46. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga
  47. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck Up

    IBD
  48. Morning Market Movers

    Benzinga
  49. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, Shares Surge

    Benzinga
  50. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
Trading Center